Antihypertensive Market includes (by Therapeutic class (Diuretics, Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta Blockers, Direct Renin Inhibitors, Calcium Channel Blockers, and Others)), and Region (North-America, Europe, Asia Pacific, Latin America, Middle East and Africa)) – is expected to reach USD 25.4 by 2026 at a CAGR of 3.2%.

Angiotensin-converting enzyme (ACE) inhibitors will be the leading type segment during the forecast period for Antihypertensive market
Among the therapeutic class, angiotensin-converting enzyme (ACE) inhibitors segment accounted for the largest share of the market in 2017, because of preferred first line of action by geriatric population and high action mechanism. It has shown a drastic effect in reducing both the cardiovascular mortality and morbidity, as these drugs are being either administered solely or in combination based on the severity of hypertension.

North America to hold the largest market share for the Antihypertensive market in forecast period of 2018-2026
North America accounted for the largest share of the antihypertensive market. Increased prevalence of hypertension and another cardiovascular disease as well as people getting more aware about the related consequences are some of the major drivers for the market growth. This along with the presence of large manufacturers have further boosted the overall market growth.

For more information visit:
https://www.maximizemarketresearch.com/market-report/global-antihypertensive-market/11342/